Clinical evaluation of the cartridge-based GeneXpert human papillomavirus assay in women referred for colposcopy

Journal of Clinical Microbiology

Volumn 52, Issue 6, 2014, Pages 2089-2095

  Einstein, Mark H ^a   Smith, Katherine M ^b   Davis, Thomas E ^c   Schmeler, Kathleen M ^d   Ferris, Daron G ^e   Savage, Ashlyn H ^f   Gray, Jermaine E ^g   Stoler, Mark H ^h   Wright Jr , Thomas C ⁱ   Ferenczy, Alex ^j   Castle, Philip E ^k  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c INDIANA UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e AUGUSTA UNIVERSITY   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^h UNIVERSITY OF VIRGINIA   (United States)

ⁱ Columbia University ^*  (United States)

^j MCGILL UNIVERSITY   (Canada)

^k Global Cancer Initiative   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER GRADING; CLINICAL EVALUATION; COLPOSCOPY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DNA DETERMINATION; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PAPILLOMAVIRUS INFECTION; POINT OF CARE TESTING; PRIORITY JOURNAL; PROCESS DEVELOPMENT; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; VALIDATION PROCESS; VIRUS DETECTION; WART VIRUS; ADOLESCENT; CLINICAL TRIAL; COMPARATIVE STUDY; CYTOCHEMISTRY; EARLY DIAGNOSIS; EVALUATION STUDY; FEMALE; ISOLATION AND PURIFICATION; MIDDLE AGED; MOLECULAR DIAGNOSIS; MULTICENTER STUDY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; PROSPECTIVE STUDY; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; EARLY DETECTION OF CANCER; FEMALE; HISTOCYTOCHEMISTRY; HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; UNITED STATES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84901649719     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00176-14     Document Type: Article

References (29)

1. Clifford GM, Smith JS, Aguado T, Franceschi S. 2003. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br. J. Cancer 89:101-105. http://dx.doi.org/10.1038/sj.bjc .6601024 (Pubitemid 36897943)
2. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. 2007. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370:59-67. http://dx.doi.org/10.1016/S0140- 6736(07)61050-2 (Pubitemid 47017468)
3. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ. 1992. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet. Gynecol. 79:328-337. http://dx.doi.org/ 10.1097/00006250-199203000-00002
4. Meyer-Rath G, Schnippel K, Long L, MacLeod W, Sanne I, Stevens W, Pillay S, Pillay Y, Rosen S. 2012. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One 7:e36966. http://dx.doi.org/10.1371/journal.pone. 0036966
5. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, Radberg T, Strander B, Forslund O, Hansson BG, Rylander E, Dillner J. 2007. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N. Engl. J. Med. 357:1589-1597. http://dx.doi.org/10.1056/NEJMoa073204 (Pubitemid 47598401)
6. Peyton CL, Gravitt PE, Hunt WC, Hundley RS, Zhao M, Apple RJ, Wheeler CM. 2001. Determinants of genital human papillomavirus detection in a US population. J. Infect. Dis. 183:1554-1564. http://dx.doi.org/10.1086/320696 (Pubitemid 32466692)
7. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, Kenter GG, Cuzick J, Snijders PJ, Meijer CJ. 2012. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 13:78-88. http://dx.doi.org/10.1016/S1470-2045(11)70296-0
8. Andrae B, Kemetli L, Sparen P, Silfverdal L, Strander B, Ryd W, Dillner J, Tornberg S. 2008. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J. Natl. Cancer Inst. 100:622-629. http://dx.doi.org/10.1093/jnci/djn099
9. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T. 2006. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 119:1095-1101. http://dx.doi.org/10.1002/ijc.21955 (Pubitemid 44116919)
10. Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, Berkhof J, Peto J, Meijer CJ. 3 November 2013. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet http://dx.doi.org/10.1016/S0140-6736(13)62218-7
11. Castle PE, de Sanjosé S, Qiao YL, Belinson JL, Lazcano-Ponce E, Kinney W. 2012. Introduction of human papillomavirus DNA screening in the world: 15 years of experience. Vaccine 30(Suppl 5):F117-F122. http://dx.doi.org/10. 1016/j.vaccine.2012.05.071
12. Castle PE, Solomon D, Wheeler CM, Gravitt PE, Wacholder S, Schiffman M. 2008. Human papillomavirus genotype specificity of hybrid capture 2. J. Clin. Microbiol. 46:2595-2604. http://dx.doi.org/10.1128/JCM.00824-08
13. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 2010. Globocan 2008: cancer incidence and mortality worldwide. IARC Canc-erBase no. 10. International Agency for Research on Cancer, Lyon, France. http://globocan.iarc. fr/Default.aspx.
14. Giannopoulos T, Butler-Manuel S, Tailor A, Demetriou E, Daborn L. 2005. Prevalence of high-grade CIN following mild dyskaryotic smears in different age groups. Cytopathology 16:277-280. http://dx.doi.org/10.1111/j.1365-2303.2005. 00301.x. (Pubitemid 41784313)
15. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlee F, Franco EL. 2007. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med. 357:1579-1588. http://dx.doi.org/10.1056/NEJMoa071430 (Pubitemid 47598400)
16. Safaeian M, Schiffman M, Gage J, Solomon D, Wheeler CM, Castle PE. 2009. Detection of precancerous cervical lesions is differential by human papillomavirus type. Cancer Res. 69:3262-3266. http://dx.doi.org/10.1158/0008- 5472.CAN-08-4192
17. Dockter J, Schroder A, Hill C, Guzenski L, Monsonego J, Giachetti C. 2009. Clinical performance of the APTIMAHPVAssay for the detection of high-risk HPV and high-grade cervical lesions. J. Clin. Virol. 45(Suppl 1):S55-S61. http://dx.doi.org/10.1016/S1386-6532(09)70009-5
18. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menéndez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, et al. 2010. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 11:1048-1056. http://dx.doi.org/10.1016/S1470-2045(10) 70230-8
19. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. 2003. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer 88:63-73. http://dx.doi.org/10.1038/sj.bjc .6600688
20. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. 2007. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer 121:621-632. http://dx.doi.org/10.1002/ijc.22527 (Pubitemid 46986496)
21. Gravitt PE, Schiffman M, Solomon D, Wheeler CM, Castle PE. 2008. A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study. Cancer Epidemiol. Biomarkers Prev. 17:1248-1254. http://dx.doi.org/10.1158/1055-9965. EPI-07-2904
22. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J, New Technologies for Cervical Cancer screening (NTCC) Working Group. 18 January 2010. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. http://dx.doi.org/10.1016/S1470-2045(09)70360-2
23. Castle PE, Cox JT, Jeronimo J, Solomon D, Wheeler CM, Gravitt PE, Schiffman M. 2008. An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL Triage Study (ALTS). Obstet. Gynecol. 111:847-856. http://dx.doi.org/10.1097/AOG.0b013e318168460b. (Pubitemid 351482616)
24. Schlecht NF, Trevisan A, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL. 2003. Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int. J. Cancer 103:519-524. http://dx.doi.org/10. 1002/ijc.10846 (Pubitemid 36020228)
25. van Duin M, Snijders PJ, Schrijnemakers HF, Voorhorst FJ, Rozendaal L, Nobbenhuis MA, van den Brule AJ, Verheijen RH, Helmerhorst TJ, Meijer CJ. 2002. Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int. J. Cancer 98:590-595. http://dx.doi.org/10.1002/ijc.10232 (Pubitemid 34208561)
26. Xi LF, Kiviat NB, Galloway DA, Zhou XH, Ho J, Koutsky LA. 2008. Effect of cervical cytologic status on the association between human papillomavirus type 16 DNA load and the risk of cervical intraepithelial neoplasia grade 3. J. Infect. Dis. 198:324-331. http://dx.doi.org/10.1086/589715
27. Guimerà N, Lloveras B, Lindeman J, Alemany L, van de Sandt M, Alejo M, Hernandez-Suarez G, Bravo IG, Molijn A, Jenkins D, Cubilla A, Muñoz N, de Sanjose S, Bosch FX, Quint W, RIS HPV TTHPV VVAPO study groups. 2013. The occasional role of low-risk human papillomaviruses 6, 11, 42, 44, and 70 in anogenital carcinoma defined by laser capture microdissection/ PCR methodology: results from a global study. Am. J. Surg. Pathol. 37: 1299-1310. http://dx.doi.org/10.1097/PAS.0b013e31828b6be4
28. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T, Joint European Cohort Study. 2008. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 337:a1754. http://dx.doi.org/10.1136/bmj.a1754
29. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, Schiffman MH, Scott DR, Apple RJ. 2000. Improved amplification of genital human papillomaviruses. J. Clin. Microbiol. 38:357-361. (Pubitemid 30043317)